Paper Details

  1. Home
  2. Paper Details

Cabozantinib in Thyroid Cancer.

Author: AntonelliAlessandro, BenvengaSalvatore, Di BariFlavia, FallahiPoupak, FerrariSilvia M, MaterazziGabriele, MiccoliPaolo

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

Cabozantinib is a multitarget tyrosine kinase inhibitor. This study reviewed the anti-cancer effects of cabozantinib in preclinical and clinical models of various cancers. Cabozantinib improved progression-free survival in patients with medullary thyroid cancer and showed promising results in patients with differentiated thyroid cancer.
Paper Details　
Original Abstract of the Article :
Cabozantinib is an oral once-daily multitarget tyrosine kinase inhibitor of MET, VEGFR2, RET, acting against KIT, AXL, FLT3 and Tie-2. Cabozantinib has shown anti-cancer effects in preclinical and clinical models of cancers derived from both epithelial and mesenchymal origins [prostate cancer, non s...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.2174/1574892810666150708110816

データ提供：米国国立医学図書館（NLM）

Cabozantinib: A Journey Through the Desert of Thyroid Cancer

Thyroid cancer presents a challenging landscape for patients and researchers alike, requiring innovative approaches to manage this complex condition. This study delves into the potential of cabozantinib, a multitarget tyrosine kinase inhibitor, as a treatment for thyroid cancer. The authors, like skilled desert explorers, navigate through the vast expanse of preclinical and clinical research, uncovering the promising effects of cabozantinib in both medullary thyroid cancer (MTC) and differentiated thyroid cancer (DTC). The study's findings highlight the potential of cabozantinib to improve progression-free survival (PFS) in MTC patients, offering a beacon of hope in the challenging terrain of this disease. This research underscores the importance of exploring targeted therapies for thyroid cancer, seeking to find effective pathways towards better treatment outcomes.

The Quest for Effective Thyroid Cancer Treatment

This study highlights the potential of cabozantinib as a promising treatment option for thyroid cancer. The research reveals its effectiveness in improving progression-free survival in MTC patients, offering a glimmer of hope in the challenging landscape of thyroid cancer. Further research is needed to explore the full potential of cabozantinib in different types of thyroid cancer, seeking to find more effective pathways towards better treatment outcomes.

Navigating the Desert of Thyroid Cancer Treatment

As a desert wanderer, I've witnessed the resilience of life even in the harshest conditions. This research reminds me of the ongoing quest for effective cancer treatments. The study's findings offer a beacon of hope, highlighting the potential of targeted therapies like cabozantinib in improving outcomes for patients battling thyroid cancer. It's a reminder that even in the vast desert of cancer treatment, there's always a path towards a brighter future.

Dr. Camel's Conclusion

This study explores the potential of cabozantinib as a treatment option for thyroid cancer. The research reveals its effectiveness in improving progression-free survival in MTC patients, offering a beacon of hope in the challenging landscape of thyroid cancer. Further research is needed to explore the full potential of cabozantinib in different types of thyroid cancer, seeking to find more effective pathways towards better treatment outcomes.
Date :
  1. Date Completed 2016-06-16
  2. Date Revised 2019-11-13
Further Info :

Pubmed ID

26152149

DOI: Digital Object Identifier

10.2174/1574892810666150708110816

Related Literature

Article Analysis
・Effects of cabozantinib (thyroid cancer)
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.